Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!

Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile.

Published on Dec 1, 1998in Diabetes 7.20
· DOI :10.2337/diabetes.47.12.1941
Lisa Getty3
Estimated H-index: 3
,
Marianthe Hamilton-Wessler11
Estimated H-index: 11
+ 2 AuthorsRichard N. Bergman103
Estimated H-index: 103
Cite
Abstract
We examined the hindlimb lymph insulin profile during simulated intravenous glucose tolerance tests (IVGTTs) in anesthetized dogs to test the following hypotheses: 1) the biphasic insulin response to intravenous glucose can be seen as a priming bolus and a secondary infusion that effect a rapid stepwise increase in the interstitial insulin concentration and 2) the activation of glucose utilization (rate of glucose uptake [Rd]) during an IVGTT is more similar to the dynamics of the interstitial insulin profile than that of the arterial plasma. Three insulin profiles were infused: a normal biphasic pattern, a second phase infusion only, and a biphasic pattern with a fourfold greater first phase and a normal second phase. During the normal biphasic infusion, lymph insulin quickly reached and maintained a steady-state concentration (10 min, 26.42 +/- 0.86 microU/ml). With second phase only, it took lymph insulin 35 min to reach a steady state of lower concentration (13.13 +/- 0.46 microU/ml) than the normal. And with a fourfold greater first phase, lymph insulin plateaued quickly (16 min, 140.87 +/- 1.68 microU/ml), but for a shorter duration than the normal. For each profile, the time course of activation of Rd did not follow the time course of insulin in the plasma, but was more similar to that of insulin in the interstitial fluid. These results show that the biphasic response allows interstitial insulin to rapidly reach and maintain a steady state beneficial to activation and maintenance of glucose utilization.
  • References (0)
  • Citations (38)
Cite
References0
Newest
Cited By38
Newest
Published on May 1, 2018in The Journal of Clinical Endocrinology and Metabolism 5.61
Cyndya Shibao22
Estimated H-index: 22
(VUMC: Vanderbilt University Medical Center),
Jorge E Celedonio1
Estimated H-index: 1
(VUMC: Vanderbilt University Medical Center)
+ 8 AuthorsNada A. Abumrad58
Estimated H-index: 58
(WashU: Washington University in St. Louis)
Published on Jul 1, 2017in Diabetes 7.20
Richard N. Bergman103
Estimated H-index: 103
(Cedars-Sinai Medical Center),
Malini S. Iyer6
Estimated H-index: 6
(Cedars-Sinai Medical Center)
On the basis of studies that investigated the intraportal versus systemic insulin infusion and transendothelial transport of insulin, we proposed the “single gateway hypothesis,” which supposes an indirect regulation of hepatic glucose production by insulin; the rate-limiting transport of insulin across the adipose tissue capillaries is responsible for the slow suppression of free fatty acids (FFAs), which in turn is responsible for delayed suppression of hepatic endogenous glucose production (E...
Published on May 1, 2015in Diabetes 7.20
Kelly A. Kaihara4
Estimated H-index: 4
(U of C: University of Chicago),
Lorna M. Dickson4
Estimated H-index: 4
(U of C: University of Chicago)
+ 3 AuthorsBarton Wicksteed18
Estimated H-index: 18
(U of C: University of Chicago)
Diabetes arises from insufficient insulin secretion and failure of the β-cell mass to persist and expand. These deficits can be treated with ligands to Gs-coupled G-protein-coupled receptors that raise β-cell cAMP. Here we studied the therapeutic potential of β-cell cAMP-dependent protein kinase (PKA) activity in restoring glucose control using β-caPKA mice. PKA activity enhanced the acute insulin response (AIR) to glucose, which is a primary determinant of the efficacy of glucose clearance. Enh...
Published on Oct 15, 2013in Javma-journal of The American Veterinary Medical Association 1.30
Rebecka S. Hess17
Estimated H-index: 17
,
Kenneth J. Drobatz29
Estimated H-index: 29
Objective—To evaluate the effects of twice-daily glargine insulin administration in dogs with diabetes mellitus. Design—Open-label, prospective clinical trial. Animals—10 dogs with naturally occurring diabetes mellitus. Procedures—Dogs with poorly regulated or newly diagnosed diabetes mellitus were enrolled if their owners agreed to return them to the hospital at 1- to 3-week intervals for 4 follow-up visits. During each follow-up visit, blood glucose concentrations were measured every 2 hours f...
Published on Mar 1, 2011in American Journal of Veterinary Research 1.07
K.R. Verkest9
Estimated H-index: 9
,
L. M. Fleeman16
Estimated H-index: 16
+ 1 AuthorsJohn M. Morton26
Estimated H-index: 26
Objective—To compare beta-cell sensitivity to glucose, first-phase insulin secretion, and glucose tolerance between dogs with naturally occurring obesity of > 2 years' duration and lean dogs. Animals—17 client-owned obese or lean dogs. Procedures—Frequently sampled IV glucose tolerance tests were performed with minimal model analysis on 6 obese dogs and matched controls. Glucagon stimulation tests were performed on 5 obese dogs and matched controls. Results—Obese dogs were half as sensitive to t...
Published on Jan 1, 2011in Asaio Journal 2.49
Magda Galach6
Estimated H-index: 6
,
Jacek Waniewski26
Estimated H-index: 26
+ 3 AuthorsBengt Lindholm73
Estimated H-index: 73
The purpose of this study was to analyze the effect of peritoneal dialysis with glucose-based solution on plasma glucose and insulin responses in patients on continuous ambulatory peritoneal dialysis (CAPD), describe the glucose-insulin system using a mathematical model, and identify abnormalities i
Published on Apr 1, 2010in Molecular Diagnosis & Therapy 3.06
Tun Jen Hsiao2
Estimated H-index: 2
(TMU: Taipei Medical University),
Lawrence Shih Hsin Wu3
Estimated H-index: 3
(TCU: Tzu Chi University)
+ 2 AuthorsEugene Lin1
Estimated H-index: 1
Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene.